Cognitive Impairment in Parkinson's Disease: Contributions from the Parkinson's Progression Markers Initiative
Daniel Weintraub1,2, Roseanne D Dobkin3, Michele K York4,5
1Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Cognitive impairment is a core feature of neuronal synuclein disease (NSD) across the Parkinson's disease (PD) continuum, emerging in prodromal states and progressing variably after diagnosis. Leveraging Parkinson's Progression Markers Initiative (PPMI) findings, we highlight that dementia risk in PD appears lower and later than historically estimated (approximately 10% at 10 years), whereas cognition is shaped by converging factors including age, education, affective symptoms, dopaminergic deficit, diffuse cortical atrophy, reduced cerebrospinal fluid (CSF) Aβ1-42, and genetic variants. These insights inform clinical research-encouraging prodromal-stage enrollment, cognition-linked functional endpoints, and platform designs-whereas myPPMI enables scalable remote phenotyping to accelerate mechanistic discovery and biologically-targeted trials of cognitive decline. ANN NEUROL 2026.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...


